TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Michigan Stroke Transitions Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Patient Inclusion Criteria:~* A final confirmed hospital diagnosis of acute stroke (ischemic or hemorrhagic).~* Patient living at home pre-stroke.~* Presence of stroke-related deficits at admission (defined as a National Institute of Health Stroke Severity score of \>=1).~* Presence of at least mild functional limitations at discharge (defined as a modified Rankin score \[mRS\] score of \>=1), or therapy ordered.~* Discharged directly home (includes patient's residence or that of a family member).~* Discharged to a rehabilitation facility (IRF or SNF) with the expectation of return to home within 4 weeks.~Patient Exclusion Criteria:~* Patients who live more than 50 miles from the hospital (for reasons related to the home visits).~* Patients discharged to nursing home, hospice care or LTCH (Long term care hospital).~* Patients who have clinically documented cognitive deficits or stroke-related impairments including aphasia sufficient to impact the consent process and for whom a proxy respondent is not available.~* Patients who fail the 6-item cognitive screening (SIS-6) for cognitive impairment (score \<=4) and for whom a proxy respondent is not available~* Patients enrolled in another acute stroke intervention trial that has a significant impact on the post-acute period (i.e., intensive data collection required of patient during follow-up).~* Limited life expectancy (\< 6 months) or significant medical comorbidity likely to impact completion of the study (e.g., severe mental illness, drug or alcohol use or dependence, metastatic cancer).~* Neither the patient nor caregiver speaks English.~Caregiver Inclusion Criteria:~* Age 18 or over.~* Are identified by the stroke patient as the primary caregiver (individual who has primary responsibility for assisting with the patient's care).~* Speaks English.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: NO_INTERVENTION): Patients in this group will receive the hospitals' usual transitional care approach.
- SCM (Type: EXPERIMENTAL): One intervention is provided:~1. SCM (Stroke Case manager): a trained social worker who provides in-home case management services.
- SCM and VSSP (Type: EXPERIMENTAL): Two interventions are provided:~1. SCM (Stroke Case manager): a trained social worker who provides in-home case management services. Plus:~2. VSSP (Virtual Stroke Support Portal): Access and training in the use of the VSSP: a purpose-built, online, patient-centered information and support resource.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Pericardial Bioprostheses in AVR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients who are going to undergo aortic valve replacement with bioprosthesis~Exclusion Criteria:~* heart failure with severe LV dysfunction (LV EF \<30%)~* active infective endocarditis~* with other critical cardiovascular disease (e.g. acute aortic dissection)~* with other critical comorbities by which the expected life span is less than 1 year~* inadequate participant by the researcher's discretion

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AVALUS group (Type: EXPERIMENTAL): patients who will undergo aortic valve replacement with Avalus bioprosthesis
- CEPME group (Type: ACTIVE_COMPARATOR): patients who will undergo aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rapip Study: Clinical Trial on Remifentanyl for Analgesia and Sedation of Ventilated Neonates and Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ventilated term newborns and infants ≤ 60 days~* Expected time of artificial ventilation between 12 and 96 hours~Exclusion Criteria:~* Neuromuscular diseases~* Drug abuse of the mother (exclusion criteria for newborns)~* Known hypersensitivity to Ultiva® or Fentanyl-Janssen®~* Missing informed consent of the parents~* Participation in another clinical trial during the last 4 weeks before start of this trial

- Gender: ALL
- Minimum Age: None
- Maximum Age: 60 Days
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Fentanyl
- 1 (Type: EXPERIMENTAL): Remifentanyl

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major inclusion criteria~* had a histologically proven adenocarcinoma of the gastroesophageal junction, or stomach that was locally advanced (inoperable) or metastatic~* measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST)1.1~* an Eastern Cooperative Oncology Group performance status of 0 to 2~* adequate renal, hepatic, and hematologic function~Major exclusion criteria~* previous chemotherapy or radiotherapy (unless in the adjuvant setting)~* uncontrolled cardiac disease, or other clinically significant, uncontrolled coexisting illness or previous or concurrent cancer~* accumulated dose of Epirubicin exceeds 300mg/m2~* HER2 positive and willing to use trastuzumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- XELOX (Type: EXPERIMENTAL): oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
- EOX (Type: ACTIVE_COMPARATOR): Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HYDEAL-D® Application for Promoting the Restoration of Sexual Function in the Postpartum Period

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women from 18 to 40 years old;~* Women in the puerperium period (after vaginal delivery or cesarean section);~* Women that are breast-feeding, that are not breast-feeding or that are breast-feeding partially;~Exclusion Criteria:~* Allergy to hyaluronic acid gel;~* Women non-Italian speaking;~* Women with signs of vaginal infection;~* Women with a history of cancer of any site with recent genital bleeding of unknown origin; and patients with acute hepatopathy, embolic disorders, severe primary disease of kidney;~* Women who are attending or have attended other clinical trials within previous two weeks;~* Women with mental disorder and no insight

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Experimental group receiving HYALOGYN® (Type: EXPERIMENTAL): None
- Control group undergoing expectant management (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled to undergo elective primary hip arthroplasty (based on an osteoarthritis diagnosis) under spinal anesthesia~* Adult male or female (surgically sterile or post-menopausal), aged 50 years or older~* American Society of Anesthesiology (ASA) Class II or III~* Physical examination, laboratory status, vital signs, and ECG within acceptable limits for the planned surgery, as judged by the investigator~* Have been given written and verbal information by the investigator about Hemospan and the protocol, and have had the opportunity to ask questions about the study~* Patients must sign an Informed Consent form that has been reviewed and approved by the independent Ethics Committee~Exclusion Criteria:~* Hip fracture patients and nail/pin extraction procedures~* Clinical evidence of uncontrolled cardiovascular, infectious, psychiatric, metabolic or systemic disorders including diabetes and rheumatoid arthritis~* Evidence of significant hypertension with SBP \>180 mmHg, or a difference in SBP obtained in each arm that is \>15 mmHg (measured in the supine position in both arms, at screening)~* Recent history or evidence of MI or stroke (within 6 months)~* Known alcohol or drug dependency~* Currently taking oral anti-coagulant therapy; except for low-dose aspirin (acetylsalicylic acid), \<200 mg/day~* History of coagulopathy~* Involved in any investigational drug or device trial within 30 days prior to this study~* Professional or ancillary personnel involved with this study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemospan (MP4OX) (Type: EXPERIMENTAL): 4.3 g/dL MalPEG-Hb solution
- Control (Type: ACTIVE_COMPARATOR): Voluven (HES 130/0.4)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male ≥18 years of age~* Severe hemophilia A (past evidence of circulating FVIII activity of \< 1% normal)~* Treated or exposed to FVIII concentrates or cryoprecipitate for at least 150 exposure days~* ≥12 bleeding episodes if receiving on-demand therapy over the preceding 12 months~* Agree to use double barrier contraceptive until at least 3 consecutive semen samples are negative for AAV 2/6 after SB-525 infusion~Exclusion Criteria:~* Presence of neutralizing antibodies~* Current inhibitor, or history of FVIII inhibitor (except for transient low titer inhibitor detected in childhood)~* History of hypersensitivity response to FVIII~* History of Hepatitis B or HIV-1/2 infection~* History of Hepatitis C, unless viral assays in two samples, collected at least 6 months apart, are negative~* Evidence of any bleeding disorder in addition to hemophilia A~* Markers of hepatic inflammation or overt or occult cirrhosis~* History of chronic renal disease or creatinine ≥ 1.5 mg/dL~* Presence of liver mass on magnetic resonance imaging (MRI), or, positive alpha fetoprotein~* Presence of \> grade 2 liver fibrosis on elastography for subjects with history of treated Hepatitis C or suspicion of chronic liver disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequential dose escalation (Type: EXPERIMENTAL): SB-525 (PF-07055480) is administered as a single infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ADHD~Exclusion Criteria:~* Psychosis~* Tourette syndrome~* Intelligence quotient (IQ) \< 70~* Pervasive developmental disorder (PDD)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Ritalin (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-CD20 in Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~People may be eligible for this study if they:~* Are 18 to 70 years of age~* Agree to use a reliable method of birth control during treatment and for 6 months after treatment ends~* Have SLE (by the American College of Rheumatology criteria)~* Have had SLE for at least 6 months prior to screening~* Have active SLE disease at the screening visit~* Have organ disease (lung, stomach, intestinal, blood, kidney, and/or heart)~* Have failed standard therapy, including at least 1 immunosuppressive agent, or have experienced side effects from an immunosuppressive agent that required discontinuation of treatment~* Meet blood, liver, and kidney laboratory values set by the protocol~* Have not taken an immunosuppressive agent for 2 weeks prior to the first treatment~* Have been on a stable dose of oral corticosteroids, if taking them, for 4 weeks before the first week's visit. Oral corticosteroids may be altered as medically necessary after enrollment.~* Have at least 1 elevated autoantibody level at screening visit.~Exclusion Criteria~People will not be eligible for this study if they:~* Are pregnant or breast-feeding~* Have heart, lung, nervous system, kidney, liver, stomach, intestinal, or other diseases that may place the patient at risk if participating in the trial~* Have cranial neuropathy (a condition affecting the head region)~* Are on blood-thinning agents to prevent blood clotting~* Have a serious skin disease~* Have a certain class of heart disease~* Have had cancer, unless surgically cured basal cell carcinoma or cervical dysplasia~* Have a long term serious infectious disease such as tuberculosis or a fungal infection that is now active, or active within 2 years of the baseline visit~* Have had HIV infection or another immunosuppressive state (chemotherapy or radiation therapy)~* Have received any experimental drug within 30 days of baseline visit~* Have received any monoclonal antibody or similar medication within 3 months of the baseline visit~* Received any intravenous, joint, or muscle injection of corticosteroids within 4 weeks of the baseline visit~* Abuse alcohol or drugs~* Are unwilling or unable to follow the protocol~* Have poor veins for receiving injections.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- rituximab (Type: EXPERIMENTAL): 375 mg/m\^2 administered intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Insomnia as defined by DSM-IV criteria and supported by subject diary~* Male or female between the ages of 18-64 years~* Body mass index (BMI) between 18-34 kg/m\^2~* Females of childbearing potential must use a medically acceptable method of contraception~* Capable of understanding and willing to comply with study procedures and has provided informed consent~Exclusion Criteria:~* Females who are pregnant, breast-feeding or have a positive pregnancy test~* Any circadian rhythm disorder including planned travel across several time zones during the study period~* Known hypersensitivity to Zolpidem~* Has performed regular shift work with the past several months prior to screening~* An acute clinically significant illness or surgery as determined by the PI within 30 days of screening~* Patients that have used any central nervous system (CNS) medication or other medication known to impact the sleep/wake cycle~* A history of psychiatric disorder as defined by DSM-IV~* A history of drug addiction or alcohol abuse~* Any current significant disease, unless adequately controlled with a protocol allowed medication~* Known history of HIV or Hepatitis B or C~* Patients who have received an investigational drug within several months of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- placebo/zolpidem 3.5/zolpidem 1.75 (Type: EXPERIMENTAL): None
- placebo/zolpidem 1.75/zolpidem 3.5 (Type: EXPERIMENTAL): None
- zolpidem 3.5/placebo/zolpidem 1.75 (Type: EXPERIMENTAL): None
- zolpidem 3.5/zolpidem 1.75/placebo (Type: EXPERIMENTAL): None
- zolpidem 1.75/placebo/zolpidem 3.5 (Type: EXPERIMENTAL): None
- zolpidem 1.75/zolpidem 3.5/placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency~Exclusion Criteria:~* Patients for whom Oxytrol(r) is contraindicated.~* Patients treated with Oxytrol(r) prior to participation in this study.~* Patients residing in long-term care facilities or nursing homes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have at least 1 previously untreated superficial basal cell carcinoma tumor~* Minimum tumor size 0.5 cm2 and maximum diameter of 2.0 cm~Exclusion Criteria:~* Evidence of clinically significant, unstable medical conditions~* Cannot have recent use of topical steroids or retinoids in the treatment area.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aldara (Type: EXPERIMENTAL): Aldara (imiquimod) cream 5% applied 7 times per week for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Children that have been vaccinated with IPV-Al AJV in the VIPV-07 and VIPV-07 E1 trials and have completed these trials~2. Healthy, as assessed from medical history and physical examination~3. Parent(s)/guardian(s), according to the local legal requirements, have been properly informed about the trial and have signed the informed consent form~4. Parent(s)/guardian(s), according to the local legal requirements, have been granted access to the child´s trial related medical records~5. Parent(s)/guardian(s), according to the local legal requirements, are likely to comply with trial procedures~Exclusion Criteria:~1. Previous vaccination with OPV~2. Previous vaccination with IPV outside the VIPV-07 and VIPV-07 E1 trials~3. Known or suspected immunodeficiency (e.g. leukaemia, lymphoma) or family history of congenital or hereditary immunodeficiency. HIV is not an exclusion criterion.~4. Severe uncontrolled chronic (e.g. neurologic, pulmonary, gastrointestinal, hepatic, renal or endocrine) disease~5. Known or suspected allergy to vaccine constituents (e.g. hypersensitivity to formaldehyde and/or 2-phenoxy-ethanol)~6. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections or blood sampling~7. Treatment with a product which is likely to modify the immune response (e.g. blood products and immunoglobulins) prior to inclusion or planned during the trial period~8. Participating in another interventional clinical trial~9. Not suitable for inclusion in the opinion of the investigator

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 4 Years
- Healthy Volunteers: t

Study Arms:
- IPV-Al AJV (Type: EXPERIMENTAL): One dose of 0.5 mL of IPV-Al AJV injected intramuscularly perpendicular to the skin in the RIGHT deltoid muscle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete